Identification of Serum Proton NMR Metabolomic Fingerprints Associated with Hepatocellular Carcinoma in Patients with Alcoholic Cirrhosis

Pierre Nahon1,4, Roland Amathieu5,6, Mohamed N. Triba5, Nadia Bouchelou6, Jean-Charles Nault1, Marianne Ziol2, Olivier Seror3, Gilles Dhonneur6, Jean-Claude Trinchet1, Michel Beaugrand1, and Laurence Le Moyec7

Abstract

Purpose: Metabolomics depicts metabolic changes in biologic systems using a multiparametric analysis technique. This study assessed the metabolomic profiles of serum, obtained by proton nuclear magnetic resonance (NMR) spectroscopy, from cirrhotic patients with and without hepatocellular carcinoma (HCC).

Experimental Design: The study included 154 consecutive patients with compensated biopsy-proven alcoholic cirrhosis. Among these, 93 had cirrhosis without HCC, 28 had biopsy-proven HCC within the Milan criteria and were eligible for curative treatment (small HCC), and 33 had HCC outside the Milan criteria (large HCC). Proton spectra were acquired at 500 MHz. An orthogonal partial latent structure [orthogonal projection to latent structure (OPLS)] analysis model was built to discriminate large HCC spectra from cirrhotic spectra. Small HCC spectra were secondarily projected using previously built OPLS discriminant components.

Results: The OPLS model showed discrimination between cirrhotic and large HCC spectra. Metabolites that significantly increased with large HCC were glutamate, acetate, and N-acetyl glycoproteins, whereas metabolites that correlated with cirrhosis were lipids and glutamine. Projection of small HCC samples into the OPLS model showed a heterogeneous distribution between large HCC and cirrhotic samples. Small HCC patients with metabolomic profile similar to those of large HCC group had higher incidences of recurrence or death during follow-up.

Conclusions: Serum NMR-based metabolomics identified metabolic fingerprints that could be specific to large HCC in cirrhotic livers. From a metabolomic standpoint, some patients with small HCC, who are eligible for curative treatments, seem to behave as patients with advanced cancerous disease. It would be useful to further prospectively investigate these patients to define a subgroup with a worse prognosis. Clínica Médica; 18(24); 6714–22. ©2012 AACR.

Introduction

Staging systems of hepatocellular carcinoma (HCC) aim to assess prognosis and to select adequate treatments for each case, particularly in patients eligible for curative procedures, such as hepatic resection, percutaneous ablation, or liver transplantation (1). However, there is still a need for biologic markers to be associated with clinical outcomes or treatment responses. A definition of the molecular classification of HCC is still preliminary and, unlike other tumors, as yet, no molecular data have been incorporated into algorithms for the routine management of liver cancer (2). A wide spectrum of serum biomarkers has been studied as potential diagnosis or prognosis tools in this setting, but their ability to refine HCC classification or to predict the patient’s outcome is still debated. Consequently, the main prognostic factors used in practice are restricted to clinical features such as tumor status and liver-function impairment linked to the underlying liver disease.

Metabolomics is an "omics" technique that is situated downstream of genomics, transcriptomics, and proteomics (3). Proton nuclear magnetic resonance (1H NMR) spectroscopy–based metabolomics can identify and quantify metabolic changes within a biologic system and has been applied to various pathologic conditions (4). The development of
Serum Metabolomics and Liver Cancer

Translational Relevance

Hepatocellular carcinoma (HCC) is one of the leading cancers worldwide in terms of incidence and mortality. Most of HCC arise on cirrhosis in western countries, alcohol intake being the main cause of cirrhosis and related HCC in these countries. The difficulties to assess the outcome of such patients stress the need to identify new biomarkers to refine the identification of those with a poorer therapeutic response. The present data enabled us to observe changes in serum metabolomic profiles in patients with advanced HCC that reflected the distinct activation or impairment of multiple biologic pathways. Furthermore, the analysis of patients with small HCC eligible for curative procedures revealed various metabolomic profiles that probably reflect differences in outcome after tumor ablation. By providing new patterns of recognition, serum metabolomic profiling may represent a clinical breakthrough to refine prognosis and to guide therapeutic procedures for these patients.

Recent studies have attempted to describe the metabolic phenotype of liver cancer in heterogeneous populations of patients with HCC using 1H NMR or mass spectroscopy. This has led to the identification of various metabolically impaired pathways in serum and urine (7–10). However, these data were obtained in small sample-sized cohorts of patients and important clinical information was lacking, such as the stage of liver cancer and the cause and degree of severity of the underlying liver disease, which can induce specific and serious serum metabolic disturbances (11). Furthermore, these studies were mostly restricted to Asian populations in whom cases of HCC were as a whole related to hepatitis C virus (HCV) or hepatitis B (HBV) chronic infections. The aim of the present study was to assess serum metabolomic profiles in a large cohort of well-characterized Caucasian patients with HCC that developed in alcoholic cirrhotic liver and classified according to their tumor status.

Patients and Methods

Patients and collection of serum samples

We considered all out-patients who were consecutively referred to our Hepatology unit for the management of cirrhosis and/or HCC between January 2009 and December 2010, and who fulfilled the following inclusion criteria: (i) biopsy-proven cirrhosis and chronic daily alcohol consumption of more than 50 g; (ii) no infection from the human immunodeficiency, hepatitis B or C viruses; (iii) compensated liver disease (Child–Pugh score <8); (iv) residence in France and of Caucasian origin; and (v) availability of frozen serum samples. Exclusion criteria were: (i) treatment of HCC before serum collection; (ii) past history or on-going extrahepatic neoplasm or inflammatory systemic disease; (iii) recent history of acute or chronic liver failure in the previous 6 months.

For each patient, the date of inclusion was the date of serum collection. Demographic, clinical, and routine biologic data were recorded at inclusion. Blood samples were drawn under fasting conditions before therapeutic management of HCC. Sera were separated and stored at −80°C until analysis. All patients gave their written consent for blood sampling. The local ethics committee approved the protocol.

HCC was diagnosed according to the Barcelona criteria (12): histologic evidence or convergent demonstration of a focal lesion more than 2 cm in size and arterial hypervascularization as assessed by 2 different imaging techniques, or the combination of 1 imaging technique that showed this morphologic aspect plus an α-fetoprotein (AFP) level of 400 ng/mL or more in patients with biopsy-proven cirrhosis.

Patients were classified according to the presence and status of HCC as follows.

1. Cirrhosis group: patients with cirrhosis without evidence of HCC at the time of inclusion, as judged by negative ultrasonographic findings, serum AFP of less than 50 ng/mL. All patients were prospectively evaluated every 6 months for HCC periodic screening for at least 1 year. None of the selected patients in this subgroup developed liver tumor during this time.

2. Small HCC group: patients with cirrhosis and small HCC within the Milan criteria (13; single tumor <5 cm or 3 nodules <3 cm) and eligible for curative treatment; all these patients underwent radiofrequency ablation (RFA) by the same operator during which a percutaneous biopsy for histologic assessment of HCC was conducted before ablation. Only patients with biopsy-proven HCC were selected in this subset. All of them were then followed-up using abdominal computed tomography (CT) scan, serum AFP assessment, and physical examination at 1 month then every 3 months. Patients with partial response at 1 month defined by a persistent enhancement of the lesion on CT scan could have been retreated by RFA. Follow-up ended at the date of death or liver transplantation, or at the last recorded visit (or information) within the last 6 months before December 2011. Overall survival was defined by the time between the day of inclusion and death, liver transplantation, or last visit recorded until December 2011. Recurrence-free survival was defined by the time between the date of inclusion and the date of HCC recurrence.

3. Large HCC group: patients with cirrhosis and large HCC outside the Milan criteria (multinodular HCC and/or tumoral portal vein thrombosis and/or extrahepatic metastases; ref. 1) with these patients being eligible for palliative treatment.
**1H NMR spectroscopy**

For NMR analysis, samples were thawed at room temperature. A volume of 0.6 mL of serum was placed into a 5-mm diameter-specific tube together with 0.1 mL of D$_2$O containing a known amount of fumaric acid (6.5 mg/mL). The deuterium oxide was used for the spectrometer locking and fumaric signal for chemical shift calibration at 6.53 parts per million (ppm). The addition of this acid solution lowered the sera pH of 0.1 units (identical for all samples). The resulting pH samples were between 8.4 and 8.7. Fumaric acid as an internal reference presents the advantages to produce a single signal located in a spectral region without other interfering resonances. The proton spectra were acquired at 500 MHz on a Varian Unity Inova spectrometer at 298 K. A signal was acquired after a 90° pulse of 32 K data points on a spectral window of 5,000 Hz. The relaxation delay was 4 seconds. The water signal was suppressed by a presaturation sequence using low-power irradiation (0.03 W for 2 seconds) on the water-signal frequency during the relaxation delay. Frequently, the CPMG sequence is used to suppress the broad signal of protein according to their short relaxation time. Because the lipid changes in the serum of patients with HCC, we have used a single pulse sequence to preserve the complete lipid profile of our spectra. The resulting free induction decays obtained with 128 transients were processed by Mestrec software. A Fourier transformation was applied with an exponential window function to produce a 1-Hz broadening line. Spectra were phased and a spline baseline correction was applied with 3 points at 0.5 and 9 ppm. The spectral region between 0 and 9 ppm was divided into 9,000 spectral regions of 0.001 ppm width, whereas Q$^2$ indicates a perfect description of the data by the model, and Q$^2$Y represents the explained variance, respectively, of the X and the Y matrices. Q$^2$Y estimates the predictability of the model. Q$^2$ = 1 indicates a perfect discrimination between X (intensity of the buckets) and Y (cirrhotic or HCC group) variables. To minimize false-positive rates in multiple comparisons of the 4,239 spectral weights on the cost of misclassification.

For validation, a receiver–operator characteristic (ROC) curve was drawn to evaluate the ability of the OPLS latent variable $T_{pred}$ to correctly classify the test set. The area under the ROC (AUROC) was calculated. A perfect discrimination corresponded to an AUROC equal to 1. An optimal cutoff value of $T_{pred}$ ($T_{opt}$) was also calculated with the Matlab function “perfcurve,” which minimize both the false-positive and false-negative cases in the test set, assuming equal weighting on the cost of misclassification.

The small HCC set was used to test the ability of the model to discriminate between small HCC observations and cirrhosis cases. False-positive and false-negative rates were calculated using the curve cutoff, $T_{opt}$, previously calculated for the test set.

A score plot illustrated the results. Each point in the score plot represented the projection of an NMR spectrum (and thus a patient’s sample) on the predictive (horizontal axis) and the first orthogonal component of the model (vertical axis).

The loading plot represents the covariance between the Y-response matrix and the signal intensity of the various spectral domains. Colors were also used in the loading plot depending of the P value associated with the correlation between the corresponding bucket intensity and the Y variable. The null hypothesis associated with the P values used in this study is that there is no correlation between X (intensity of the buckets) and Y (cirrhotic group or HCC group) variables. To minimize false-positive rates in multiple comparisons of the 4,239 spectral domains, we used the conservative Bonferroni correction, which discards any low significant variables. Thus, for an error rate of 0.01, a metabolite variation in the loading plot was considered significant if its P value was less than $2.4 \times 10^{-6}$.
PCA and OPLS analyses were conducted using Simca-P12 (Umetrics) and in-house Matlab (Mathworks) code based on Trygg and Wold method (14).

Metabolite identification
On the loading plot, the positive signals corresponded to those metabolites that had an increased concentration in the serum of patients with HCC. Conversely, a negative signal corresponded to those metabolites that had an increased concentration in the serum of patients without HCC.

The buckets were designated according to their central chemical-shift values. Their most probable assignment to a metabolite was given according to the spectral assignment, as previously described in the literature (15), and was confirmed with 1H–1H TOCSY 2D NMR spectra.

Results
Patients' characteristics
A total of 286 patients were screened: of these, 158 patients fulfilled the inclusion criteria as shown in Fig. 1. The data obtained by bucketing of the 158 serum spectra were successfully acquired and first analyzed by PCA (results not shown). From this analysis, 4 outliers were identified. All spectra that exhibited high levels of ethanol (1.11 and 3.66 ppm) were excluded. Demographics, clinical, and biologic features, as well as data about characteristics of liver tumors for the 154 remaining patients, are displayed in Table 1. As expected, patients with HCC were older and were more often male than patients without HCC. There was no difference in the severity of liver disease as assessed by the Model for End-Stage Liver Disease (MELD) score between the 3 groups.

OPLS model with cirrhosis and large HCC
Serum spectra from cirrhotic and large HCC groups that belonged to the training set were discriminated with the OPLS model as shown in the score plot in Fig. 2A. The model was build with 1 predictive and 3 Y-orthogonal components and exhibited a good explained variance: (R²X) of 0.46, (R²Y) of 0.90, predictability (Q²Y) of 0.83.

The model was internally validated, as all Q²Y and R²Y values obtained with permuted Y were smaller than those of the model. Intercept values for Q²Y and R²Y obtained from the permutation plot (not shown) were, respectively, −0.57 and 1.40.

Validation conducted with the test set shows that the model could predict cirrhosis or HCC as shown in the score plot in Fig. 3A. In all cases, each sample was correctly classified according to the presence or absence of large HCC. Consequently, the AUROC was equal to 1 (not shown). The optimal cutoff value of T_pred was T_opt = 0.25.

Small HCC set
As shown in the score plot in Fig. 3B the projection of cirrhotic and small HCC on the predictive component was heterogeneous.

Using the optimal cutoff value of T_pred obtained from the test set (T_opt = 0.25), all cirrhotic sera were correctly assigned to the cirrhotic groups but, among the 28 small

---

Figure 1. Flow chart of patients. CPT, Child–Pugh–Turcott score; AoCLF, acute on chronic liver failure.
The appearance of $^1$H NMR serum spectra was globally similar to those previously described in human sera of cirrhotic patients (Supplementary Fig. S1; ref. 11). The spectral assignment was confirmed with $^1$H–$^1$H TOCSY 2D NMR spectra (Supplementary Fig. S2).

The loading plot obtained with the OPLS model for the training set revealed that 12 signals, corresponding to 8 metabolites or groups of metabolites, were highly significantly correlated with the presence of large HCC (Fig. 2B). They are presented in Table 3.
HCC when compared with those without HCC. This signal corresponded to different N-acetylated glycoproteins as well as to their metabolites: N-acetylneuraminic acid and N-acetylglycosamine.

Some amino acids were identified in the spectra and were highly significant for discrimination. Glutamine was significantly higher in cirrhotic patients than patients with HCC, whereas glutamate was significantly lower.

Ketone bodies could be detected in the spectra and participated in discrimination. Acetate (1.92 ppm) was significantly higher in HCC than cirrhotic patients.

**Discussion**

This preliminary study was conducted in a homogeneous and large sample-sized cohort of patients. The usual major limitation encountered in a translational metabolomic approach to liver diseases is methodologic bias when selecting patients, thus limiting the confidence that can be drawn from conclusions (8, 9, 16). We attempted to avoid these pitfalls by constructing well-defined subgroups of patients according to their stage of underlying liver disease and HCC status. We also focused specifically on alcoholic etiology to avoid any potential specific influence of viral or nonalcoholic-related liver disease on sera metabolomic profiles, as previously reported (17, 18). Moreover, to eliminate the effect of liver-function impairment on different metabolic pathways (as previously reported), we excluded all patients with end-stage liver disease from this analysis (11). Also, the collection of sera samples before the onset of any therapeutic procedure for HCC reinforced the confidence of the observed effect of tumor metabolism.

In this setting, the present data enabled us to draw several conclusions. First, it seems that changes in serum metabolomic profiles were observed according to the presence of advanced HCC. Second, these fingerprints reflected the distinct activation or impairment of multiple biologic pathways, mainly energetic metabolism involving glutamine/glutamate, ketone bodies, and lipids. On another hand, glucose sera content was not a discriminant metabolite. Finally, the refinement of our initial projection, to analyze metabolic changes observed in patients with biopsy-proven small HCC, revealed various profiles that probably reflect different metabolic activities with potential clinical implications.

The metabolic profiles of cirrhotic patients with large HCC exhibited clear modifications in lipid composition,
that HDL level is altered and decreased with the severity of chronic liver failure (11). Patients with end-stage liver disease were excluded, thus, differences in HDL could not be explained by the severity of liver disease. Interestingly, several epidemiologic studies have reported a good correlation between low HDL-cholesterol levels and several cancers, including HCC (21). In the population studied here, cholesterolemia was not modifying in the presence of HCC (Table 1). Nevertheless, the lipoprotein profile, as assessed with NMR spectra, showed that HDL fraction (not HDL-cholesterol) could be modulated in sera of patients with HCC. However, low HDL levels may be a nonspecific surrogate marker for an existing malignancy rather than a predisposing factor. Unsaturated lipids were also found at higher levels in patients without cancer.

Glutaminolysis and glycolysis represent the main metabolic energy pathways in cell tumors. Alterations in glutamine metabolism in this context may have several explanations. First, “trapping” of glutamine by malignant cells could explain the glutamine depletion in the serum of HCC patients when compared with the cirrhotic patients in our study. Yang and colleagues showed, using high resolution magic angle spinning spectroscopy, in simultaneous samples of HCC and non-HCC tissues obtained from the same patients, elevated levels of glutamine in tumor samples: the levels were higher in high-grade tumors than low-grade or nontumoral tissues (20). Glutamine consumption by tumor cells has been reported and seems to depend upon the presence or absence of an alternative energy substrate (22). Moreover, low levels of glutamine and high levels of glutamate in serum may be found in different states as cachexia, cancer (specifically digestive cancers) or proinflammatory states. In these clinical settings, high glutamate levels were secondary to the accumulation of this metabolite in the serum in parallel with a decrease in muscular glutamate intake (23).

The role of glycoproteins in cancer disease has been widely studied. Using data from 1H NMR spectroscopy of

![Table 2. Characteristics of small HCC according to their projection on the model](https://example.com/table2.png)

<table>
<thead>
<tr>
<th></th>
<th>False negative&lt;sup&gt;a&lt;/sup&gt;</th>
<th>True positive&lt;sup&gt;d&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y&lt;sup&gt;b&lt;/sup&gt;</td>
<td>64.8 ± 1.7</td>
<td>69.9 ± 1.8</td>
</tr>
<tr>
<td>Male gender&lt;sup&gt;b&lt;/sup&gt;</td>
<td>12/17</td>
<td>10/11</td>
</tr>
<tr>
<td>Child</td>
<td>5.2 ± 0.1</td>
<td>6.1 ± 0.3</td>
</tr>
<tr>
<td>MELD</td>
<td>9.9 ± 0.5</td>
<td>11.5 ± 1.2</td>
</tr>
<tr>
<td>Number of tumors</td>
<td>1.3 ± 0.1</td>
<td>1.2 ± 0.1</td>
</tr>
<tr>
<td>Size of tumors (mm)</td>
<td>33.2 ± 4.5</td>
<td>30.1 ± 3.1</td>
</tr>
<tr>
<td>Edmondson grade (1/2/3)</td>
<td>3/11/3</td>
<td>2/7/2</td>
</tr>
<tr>
<td>Liver glutamine synthase&lt;sup&gt;e&lt;/sup&gt;</td>
<td>38%</td>
<td>25%</td>
</tr>
<tr>
<td>Recurrence&lt;sup&gt;b&lt;/sup&gt;</td>
<td>7 (41%)</td>
<td>7 (63%)</td>
</tr>
<tr>
<td>Overall mortality&lt;sup&gt;b&lt;/sup&gt;</td>
<td>4 (23%)</td>
<td>6 (54%)</td>
</tr>
</tbody>
</table>

<sup>a</sup>Mean ± SEM.

<sup>b</sup>Number (percentage) of patients.

<sup>c</sup>False negative corresponds to proven-biopsy HCC case projected with the cirrhosis cases.

<sup>d</sup>True positive corresponds to proven-biopsy HCC case projected with large HCC cases.

<sup>e</sup>Glutaminolysis and glycolysis represent the main metabolic energy pathways in cell tumors. Alterations in glutamine metabolism in this context may have several explanations. First, “trapping” of glutamine by malignant cells could explain the glutamine depletion in the serum of HCC patients when compared with the cirrhotic patients in our study. Yang and colleagues showed, using high resolution magic angle spinning spectroscopy, in simultaneous samples of HCC and non-HCC tissues obtained from the same patients, elevated levels of glutamine in tumor samples: the levels were higher in high-grade tumors than low-grade or nontumoral tissues (20). Glutamine consumption by tumor cells has been reported and seems to depend upon the presence or absence of an alternative energy substrate (22). Moreover, low levels of glutamine and high levels of glutamate in serum may be found in different states as cachexia, cancer (specifically digestive cancers) or proinflammatory states. In these clinical settings, high glutamate levels were secondary to the accumulation of this metabolite in the serum in parallel with a decrease in muscular glutamate intake (23).

The role of glycoproteins in cancer disease has been widely studied. Using data from 1H NMR spectroscopy of

![Table 3. Discriminant metabolites observed by 1H NMR spectroscopy, according to the loading plot (Fig. 2B), between cirrhotic serum spectra and large HCC serum spectra](https://example.com/table3.png)

<table>
<thead>
<tr>
<th>Number</th>
<th>Name</th>
<th>Chemical shift (ppm) and multiplicity</th>
<th>r</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Methyl moieties of fatty acids (HDL)</td>
<td>0.84&lt;sup&gt;m&lt;/sup&gt;1.23&lt;sup&gt;m&lt;/sup&gt;</td>
<td>−0.60</td>
<td>5.22 × 10&lt;sup&gt;−9&lt;/sup&gt;</td>
</tr>
<tr>
<td>2</td>
<td>Methylenes moieties of fatty acids</td>
<td>1.50&lt;sup&gt;m&lt;/sup&gt;</td>
<td>−0.56</td>
<td>4.09 × 10&lt;sup&gt;−6&lt;/sup&gt;</td>
</tr>
<tr>
<td>3</td>
<td>Acetate</td>
<td>1.90&lt;sup&gt;a&lt;/sup&gt;</td>
<td>+0.57</td>
<td>2.56 × 10&lt;sup&gt;−8&lt;/sup&gt;</td>
</tr>
<tr>
<td>4</td>
<td>Methylenes moieties of fatty acids (β of esters)</td>
<td>1.99&lt;sup&gt;b&lt;/sup&gt;</td>
<td>−0.48</td>
<td>5.42 × 10&lt;sup&gt;−6&lt;/sup&gt;</td>
</tr>
<tr>
<td>5</td>
<td>N-acetyl moiety</td>
<td>2.02&lt;sup&gt;m&lt;/sup&gt;</td>
<td>+0.52</td>
<td>5.68 × 10&lt;sup&gt;−7&lt;/sup&gt;</td>
</tr>
<tr>
<td>6</td>
<td>Glutamate</td>
<td>2.33&lt;sup&gt;m&lt;/sup&gt;</td>
<td>+0.83</td>
<td>1.23 × 10&lt;sup&gt;−21&lt;/sup&gt;</td>
</tr>
<tr>
<td>7</td>
<td>Glutamine</td>
<td>2.11&lt;sup&gt;m&lt;/sup&gt;2.43&lt;sup&gt;m&lt;/sup&gt;</td>
<td>−0.63</td>
<td>3.92 × 10&lt;sup&gt;−12&lt;/sup&gt;</td>
</tr>
<tr>
<td>8</td>
<td>Fatty acids double bounds</td>
<td>5.33&lt;sup&gt;b&lt;/sup&gt;</td>
<td>−0.42</td>
<td>6.50 × 10&lt;sup&gt;−7&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

NOTE: The metabolite number corresponds to the label in the loading plot in Fig. 2B. Chemical shift (referenced to fumaric acid signal at 6.53 ppm) and multiplicity correspond to those found in the 1H NMR spectra of the patient’s serum at 298 K. <sup>a</sup>singlet; <sup>d</sup>doubtlet; <sup>dd</sup>doublet of doublet; <sup>t</sup>triplet; <sup>mm</sup>multiplet; <sup>b</sup>broadsignal. A negative correlation (r) corresponds of an increased metabolite concentration in the cirrhotic group and a positive correlation to an increased metabolite concentration in the HCC group.
serum or plasma, the prominent resonance in the region of 2.0 to 2.1 ppm has been frequently associated with tumor invasion or malignancy in several types of cancer, including colorectal, gastric, breast, cervical, prostate, and ovarian (6). Nicholson and colleagues have suggested that this resonance arises mainly from N-acetyl protons from α1 acid glycoprotein. This glycoprotein contains a high ratio of carbohydrate (45%), as N-linked glycans of a sialic-acid type (15). More specifically, in HCC, raised levels of α1 acid glycoprotein had been found in patients with cancer, as well as low AFP, when compared with cirrhotic patients without cancer (24).

Thus, serum metabolomic analysis of cirrhotic patients with large HCC highlights the activation of various metabolic pathways that seem to be specific to this tumor. On the basis of the present data, metabolomic NMR analysis provides new insights into the metabolic processes related to the biology of liver cancer. Furthermore, the projection of small HCC serum samples along predefined discriminant axes reveals important clinical information. Indeed, based on the serum analysis of these “intermediate” patients, we were able to observe a subgroup of patients whose metabolomic profiles were similar to those of patients with large HCC, whereas other “intermediate” patients displayed fingerprints suggesting an absence of liver cancer.

The model failed to clearly discriminate between cirrhotic patients and small HCC patients. However, from a metabolomic point of view, some patients with small HCC, who were eligible for curative treatment, seemed to behave as patients with advanced cancerous disease.

HCC recurrence after curative treatment (whether RFA, surgical resection, or transplantation) is a major challenge as tumor recurrence can be as high as 50% at 2 years (1). Thus, we attempted to classify patients with small HCC according to their serum metabolomic profile and compared HCC characteristics within this subgroup (Table 2). We did not observe any differences according to clinical characteristics or HCC status (number, size, histologic features comprising expression of glutamine synthase): this suggests a certain degree of homogeneity that does not account for the identified metabolomic changes. However, there was a trend toward a worse prognosis in patients with profiles similar to the large HCC group, with higher rates of local or distant recurrences and a greater incidence of death, although these findings must be cautiously interpreted because of the small sample-size of this subpopulation (25). By providing new patterns of recognition, metabolomic profiling may be a useful tool to refine prognosis and to aid therapeutic procedures for these patients.

However, metabolomic profiling, which assesses surrogate markers of tumor biology in tumor tissues or serum samples, can provide complete and multivariate information on metabolic changes related to liver tumors and can possibly assess its aggressiveness, thus defining various metabolic profiles. The assessment of this technique as a prognosis tool in patients with HCC and who are eligible for curative treatment deserves further investigation, particularly in HCV- or HBV-infected patients with HCC in whom metabolomic changes reported here may not be entirely translated. Most importantly, the intraindividual analysis of serum changes during follow-up of treated patients may provide essential information related to therapeutic responses, recurrence, or progression. These new approaches should be developed in large prospective cohorts of well-defined patients undergoing standardized therapeutic procedures classified according to both the etiology on the underlying liver disease and the stage of liver tumor, and in whom sequential biologic samples are available for metabolomic profiling. Finally, the additional integration of metabolomic information, which may improve the performance of preexisting risk-assessment models for HCC occurrence or recurrence after treatment, warrants to be tested in large cohorts of prospective followed-up patients with cirrhosis. Such approach will surely improve our understanding of the implications of the various biologic pathways involved in the progression toward cancer diseases and may, in the near future, help identify subgroups of patients at high risk of HCC, and so could benefit from specific preventive measures or could be given adapted screening policies.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Authors’ Contributions
Conception and design: P. Nahon, R. Amathieu, O. Seror, J.-C. Trinchet, M. Beaugrand, L. Le Moyec
Development of methodology: P. Nahon, R. Amathieu, M.N. Triba, L. Le Moyec
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): P. Nahon, R. Amathieu, N. Bouchemal, J.-C. Nault, M. Ziol, O. Seror
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): P. Nahon, R. Amathieu, M.N. Triba, J.-C. Nault, O. Seror, G. Dhommeur, J.-C. Trinchet, M. Beaugrand, L. Le Moyec
Writing, review, and/or revision of the manuscript: P. Nahon, R. Amathieu, M.N. Triba, G. Seror
Study supervision: P. Nahon, R. Amathieu, L. Le Moyec

Grant Support
This work was supported by grants from Paris 13 University.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received April 7, 2012; revised September 10, 2012; accepted October 10, 2012; published OnlineFirst November 7, 2012.

References
2. Breuhahn K, Gores G, Schirmacher P. Strategies for hepatocellular carcinoma therapy and diagnostics: lessons learned from high


